Richard B. Moss, MD, is former chief of the Pediatric Pulmonary and Allergy Divisions, and allergy-immunology and pulmonary fellowship training programs director, at Stanford University. He was educated at Columbia (BA), SUNY Downstate (MD), Northwestern/Children’s Memorial Hospital (pediatrics residency) and Stanford (allergy-immunology, pulmonology fellowships). He was Director of the Cystic Fibrosis Center at Stanford (1991-2009) and site principal investigator for the Cystic Fibrosis Therapeutics Development Network (1999-2009), where he was also inaugural Chair of the Protocol Review Committee. He currently is a member of Stanford’s Child Health Research Institute, serves on the Pediatric Mentoring Program at Stanford, the Executive Committee of Stanford’s NIH clinical research program (Spectrum Child Health) and the Stanford IRB. Dr. Moss has reviewed and consulted for the NIH, CFF, national and international foundations, peer-review journals and biopharmaceutical companies. His research interests include immunopathogenesis, outcome measures, and treatment of chronic airway diseases of childhood. Recent work has focused on allergic fungal lung disease.

I am interested in the pathogenesis of chronic airways diseases of childhood. My work includes basic and clinical research. In the area of basic research, my laboratory has focused on immunoregulation of inflammation in cystic fibrosis, finding deficiencies of activated T cells from CF patients in production of counter-regulatory cytokines (IL-10, IFN-gamma) and redox metabolism. In the arena of clinical research, as a member of the CFF Therapeutics Development Network our research group conducts many trials. I have particular interests in the areas of aerosol therapy with drugs, biologics and gene vectors; mechanisms of pulmonary inflammation and immunomodulatory therapy; and corrrection of CFTR-dependent cell biology defects. We are also investigating new treatments for CF complications such as diabetes and osteoporosis, internet-based disease management, and trials of asthma drugs.